|
gptkbp:instanceOf
|
gptkb:drug
thiazide diuretic
|
|
gptkbp:ATCCode
|
C03AA03
|
|
gptkbp:bioavailability
|
60-80%
|
|
gptkbp:brand
|
Esidrix
Hydrodiuril
Microzide
Oretic
|
|
gptkbp:CASNumber
|
58-93-5
|
|
gptkbp:combines
|
gptkb:valsartan
gptkb:spironolactone
gptkb:atenolol
gptkb:metoprolol
gptkb:losartan
gptkb:lisinopril
|
|
gptkbp:contraindication
|
hypersensitivity to sulfonamides
anuria
|
|
gptkbp:discoveredBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
6-15 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C7H8ClN3O4S2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
hydrochlorothiazide
|
|
gptkbp:introducedIn
|
1959
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits sodium reabsorption in the distal convoluted tubule
|
|
gptkbp:meltingPoint
|
273–275 °C
|
|
gptkbp:metabolism
|
not significantly metabolized
|
|
gptkbp:pregnancyCategory
|
B (US)
B1 (Australia)
|
|
gptkbp:proteinBinding
|
40-70%
|
|
gptkbp:PubChem_CID
|
3513
3639
CHEMBL14
DB00999
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
hypokalemia
hyponatremia
photosensitivity
hyperglycemia
hyperuricemia
|
|
gptkbp:solubility
|
very slightly soluble
|
|
gptkbp:synonym
|
HCTZ
|
|
gptkbp:UNII
|
0J48LPH2TH
|
|
gptkbp:usedFor
|
gptkb:diabetes_insipidus
congestive heart failure
edema
hypertension
nephrotic syndrome
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:valsartan
gptkb:Hyzaar
gptkb:Quintaril
|
|
gptkbp:bfsLayer
|
6
|